Novo Nordisk, the Danish pharmaceutical giant has struck a partnership with OpenAI to integrate artificial intelligence across its entire business,
As the race to dominate the growing weight-loss drug market intensifies, the maker of Ozempic and Wegovy, announced the deal today stating that the partnership builds on Novo’s existing AI initiatives, including a research collaboration with Nvidia announced last year
Novo is fighting to regain ground against US rival Eli Lilly in the fiercely competitive weight-loss drug market. Though Novo pioneered the current generation of GLP-1 medicines, it has steadily lost market share to Lilly’s Mounjaro and Zepbound. The company’s stock has dropped more than 24% this year, partly due to disappointing clinical trial results for its next-generation drug CagriSema .
The OpenAI partnership aims to speed up everything from identifying promising drug targets to designing clinical trials and analyzing complex datasets. Novo CEO Mike Doustdar described the shift as comparable to moving from fax machines to email .
“This is not about replacing the scientist, it’s about supercharging them,” Doustdar said .
Pilot programs will begin in research and development, manufacturing, and commercial operations, with full integration expected by year-end. Novo employees already had access to a customized version of ChatGPT, but the new agreement expands capabilities significantly .
OpenAI CEO Sam Altman framed the collaboration broadly: “AI is reshaping industries and in life sciences, it can help people live better, longer lives”.
The deal shows growing pressure on pharmaceutical companies to cut development timelines and costs. Traditional drug discovery typically takes over a decade and billions of dollars. AI offers the promise of identifying patterns in vast datasets that human researchers might miss, testing hypotheses faster, and optimizing clinical trial design .
However, for Novo, the stakes extend beyond business metrics. With millions of patients worldwide awaiting new treatment options, the company is betting that AI can help it discover therapies that remain hidden in plain sight,and deliver them to patients sooner
Read also: Apple tests multiple smart glasses designs ahead of expected 2027 launch